Skip to content
Sign in

HELX · BATS · ETF

Franklin Genomic Advancements ETF (HELX) Price, Holdings & Fees

$790.03+0.05%+$0.41End-of-day price as of Oct 9, 2026

Franklin Genomic Advancements ETF (HELX) closed at $790.03 on Oct 9, 2026, up 0.05% from the previous close of $789.62.

Share price, past year

1Y +28.05%

52-week range $616.28 – $819.29. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$790.03
Sep 30, 2026$787.84
Aug 31, 2026$813.79
Jul 31, 2026$803.06
Jun 30, 2026$777.23
May 29, 2026$736.49
Apr 30, 2026$767.70
Mar 31, 2026$791.91
Feb 27, 2026$767.57
Jan 30, 2026$712.07
Dec 31, 2025$700.64
Nov 28, 2025$660.98
Oct 31, 2025$653.21

Key statistics

Expense ratio
0.50%
as of Mar 31, 2025
Net assets
$27.9M
as of Jun 30, 2026
Holdings
63
as of Jun 30, 2026
52-week range
$616.28 – $819.29

Franklin Genomic Advancements ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

Holdings

Franklin Genomic Advancements ETF held 63 investments worth $27.94M as of Jun 30, 2026. Its largest holding was GUARDANT HEALTH INC, at 9.09% of the fund.

Franklin Genomic Advancements ETF largest holdings by share of net assets
#Holding% of fundValue
1GUARDANT HEALTH INCGH9.09%$2.54M
2NATERA INCNTRA7.46%$2.08M
3KRYSTAL BIOTECH INCKRYS6.33%$1.77M
4LIGAND PHARMACEUTICALS INCLGND4.62%$1.29M
5ADAPTIVE BIOTECHNOLOGIES CORPADPT3.99%$1.11M
6UNITED THERAPEUTICS CORPUTHR3.51%$980.17K
7BRIDGEBIO PHARMA INCBBIO3.50%$977.85K
8ELI LILLY & COMPANYLLY2.95%$825.21K
9TWIST BIOSCIENCE CORPTWST2.85%$795.88K
10VERTEX PHARMACEUTICALS INCVRTX2.75%$767.45K
11ASTRAZENECA PLCAZN2.70%$754.50K
12TRAVERE THERAPEUTICS INCTVTX2.59%$724.50K
13INSMED INCINSM2.44%$681.09K
14SAMSUNG BIOLOGICS CO LTD2.26%$630.27K
15CORTEVA INCCTVA2.25%$629.67K
16MEDPACE HOLDINGS INCMEDP2.15%$600.03K
17ALNYLAM PHARMACEUTICALS INCALNY1.96%$546.67K
18TEMPUS AI INCTEM1.95%$544.37K
19IONIS PHARMACEUTICALS INCIONS1.91%$534.34K
20NEUROCRINE BIOSCIENCES INCNBIX1.84%$515.38K
21REGENERON PHARMACEUTICALS INCREGN1.80%$501.95K
22VERACYTE INCVCYT1.64%$459.21K
23ARGENX SEARGX1.64%$458.27K
24PTC THERAPEUTICS INCPTCT1.46%$408.58K
25BIONTECH SEBNTX1.38%$386.72K

Top 25 of 63 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

Franklin Genomic Advancements ETF holdings by asset type
Asset type% of fund
Stocks97.88%
Preferred stock0.85%
Franklin Genomic Advancements ETF holdings by country, largest 8
Country% of fund
United States86.61%
United Kingdom3.04%
South Korea2.63%
Germany2.23%
Netherlands2.12%
Switzerland1.21%
Ireland0.78%
Singapore0.10%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, Franklin Genomic Advancements ETF's total return was +20.94%, as reported to the SEC.

Franklin Genomic Advancements ETF monthly total returns
MonthTotal return
Jun 30, 2026+12.71%
May 31, 2026+5.99%
Apr 30, 2026+1.24%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Franklin Genomic Advancements ETF
Ticker
HELX
Exchange
BATS
Fund type
ETF
Trust
Franklin Templeton ETF Trust
SEC series ID
S000067393
SEC CIK
0001655589
Fractional shares
No

Recent SEC filings

Shareholder reports and prospectuses are filed by Franklin Templeton ETF Trust, the trust behind Franklin Genomic Advancements ETF, and cover all of its funds.

Frequently asked questions

What is HELX's price?

Franklin Genomic Advancements ETF (HELX) closed at $790.03 on Oct 9, 2026, up 0.05% from the previous close of $789.62.

What is HELX's expense ratio?

Franklin Genomic Advancements ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

What does HELX hold?

Franklin Genomic Advancements ETF held 63 investments worth $27.94M as of Jun 30, 2026. Its largest holding was GUARDANT HEALTH INC, at 9.09% of the fund. Its five largest holdings were GUARDANT HEALTH INC, NATERA INC, KRYSTAL BIOTECH INC, LIGAND PHARMACEUTICALS INC, ADAPTIVE BIOTECHNOLOGIES CORP.

How has HELX performed?

Over the 3 months to Jun 30, 2026, Franklin Genomic Advancements ETF's total return was +20.94%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 27, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2025. Prices are generated sample data for development. Data sources and disclosures